Education
About Us
Working with TipRanks
Follow Us
Sol-Gel Technologies (SLGL)
NASDAQ:SLGL
SLGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.33 - $1.65
Previous CloseN/A
Volume503.92K
Average Volume (3M)36.53K
Market Cap
$15.57M
Enterprise Value-$7.80M
Total Cash (Recent Filing)$5.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 09, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding27,857,620
10 Day Avg. Volume22,817
30 Day Avg. Volume36,528
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.32
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.35
Enterprise Value/Ebitda0.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Sol-Gel Technologies News
PremiumCompany Announcements
Sol-Gel Technologies Schedules Shareholder Meeting to Vote on Key Proposals
PremiumCompany Announcements
Sol-Gel Technologies Reports Strong Q3 2024 Results
PremiumCompany Announcements
Sol-Gel Technologies Gains Nasdaq Extension for Compliance---
Ownership Overview
―
Insiders
0.05% Mutual Funds
17.71% Other Institutional Investors
82.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $0.33 and its highest was $1.65 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $15.57M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is May 09, 2025 which is in 43 days.
How were Sol-Gel Technologies’s earnings last quarter?
Currently, no data Available
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Overvalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate is -0.11.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 27,857,620 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
---
Sol-Gel Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.36%
12-Months-Change
Fundamentals
Return on Equity
-24.59%
Trailing 12-Months
Asset Growth
-13.80%
Trailing 12-Months
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
---
SLGL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Bausch Health Companies
―
Aclaris Therapeutics
―
Arcutis Biotherapeutics
―
Ventyx Biosciences
―
Journey Medical Corp
―
Best Analysts Covering SLGL
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-48.47%
reiterated a buy rating 7 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -48.47% per trade.
---